FKBP prolyl isomerase family member 1CGenealiases: []
Q-omics provides the consensus-scored FKBP1C profile across patient tissues and cancer cell-line models. FKBP1C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FKBP1C is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, FKBP1C RNA expression shows 15,538 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where FKBP1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FKBP1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FKBP1C survival associations across molecular data types. FKBP1C RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FKBP1C RNA expression–survival associations across cancer types. High FKBP1C expression shows unfavorable associations in UVM, ACC, LIHC, LUAD and LGG, but favorable associations in CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for FKBP1C RNA expression.
This table summarizes FKBP1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FKBP1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FKBP1C shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, STAD and CHOL. The HNSC box plot shows higher FKBP1C RNA expression in tumor versus normal tissue (log2 FC = +0.818, t-test p < 0.001).
This table shows molecular features associated with FKBP1C in patient tissues and cancer cell lines. In patient samples, FKBP1C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FKBP1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
